Cancer patients don’t just fight the disease – they fight the system. Today, life-saving treatments are routinely delayed by days or even weeks due to manual, error-prone workflows. To solve this, RISA Labs has raised a $3.5M funding round to help healthcare organizations eliminate one of the most persistent barriers to timely cancer care: prior authorization delays. RISA Labs has already proven that faster care is possible by dramatically reducing manual workflows and administrative burden.
The seed was led by Binny Bansal (Flipkart co-founder) with participation from Oncology Ventures, General Catalyst, z21 Ventures, ODD BIRD VC, and Ashish Gupta. The capital will accelerate deployments in the next 100 cancer centers across the country within the next two years.
RISA’s platform—Business Operating System as a Service (BOSS) – is not another automation bot or AI assistant. It’s a full-stack orchestration engine built for the vertical complexity of healthcare, Instead of relying on humans to push paperwork or brittle bots that break when systems change, BOSS decomposes complex workflows into micro-tasks, then delegates them to a network of intelligent agents—LLMs, digital twins, and reinforcement learners, extending across an institution’s entire software stack. This allows BOSS to create a parallel digital workforce, operating on behalf of teams and alongside them. A 1,000-person institution can function like a 2,000-person one overnight, with digital agents making up half the workforce.
At a leading US cancer center, BOSS reduced prior authorization times from 30 minutes to under five. In just a few months, it processed over $1 million in medications, freed up 80 percent of staff time, and cut administrative costs by 66 percent.
Based in Silicon Valley, RISA is founded by IIT Kanpur alumni and repeat founders, Kshitij Jaggi (CEO) and Kumar Shivang (CTO) who’ve been friends for more than a decade now, who’ve previously built and scaled Urban Health. Their frustration with fragmented, slow, and error-prone healthcare workflows during that journey inspired the duo to take a systems-first approach, leading them to develop a foundational AI operating system that can simulate, understand, and orchestrate entire institutional workflows from end to end.
RISA’s founding team first explored these concepts through research, co-authoring ‘Digital Twin Ecosystem in Oncology Clinical Operations’—an early effort to envision smarter, AI-driven cancer care workflows. This foundational work laid the conceptual groundwork that later translated into tangible improvements in real-world oncology operations.
Looking ahead, RISA plans to extend across multiple nodes within the oncology ecosystem, positioning itself as the AI transformation partner for both operational and clinical workflows. This includes enabling coordination and intelligence across providers, life sciences organizations, and other stakeholders throughout the journey of a drug – extending the company’s long term vision to building a unified layer for AI-driven orchestration in oncology.
Like this:
Like Loading...
Related
This entry was posted on April 17, 2025 at 9:34 am and is filed under Commentary with tags RISA Labs. You can follow any responses to this entry through the RSS 2.0 feed.
You can leave a response, or trackback from your own site.
RISA Labs Raises $3.5M to Eliminate Treatment Delays with AI-Powered Workflow Automation in Oncology
Cancer patients don’t just fight the disease – they fight the system. Today, life-saving treatments are routinely delayed by days or even weeks due to manual, error-prone workflows. To solve this, RISA Labs has raised a $3.5M funding round to help healthcare organizations eliminate one of the most persistent barriers to timely cancer care: prior authorization delays. RISA Labs has already proven that faster care is possible by dramatically reducing manual workflows and administrative burden.
The seed was led by Binny Bansal (Flipkart co-founder) with participation from Oncology Ventures, General Catalyst, z21 Ventures, ODD BIRD VC, and Ashish Gupta. The capital will accelerate deployments in the next 100 cancer centers across the country within the next two years.
RISA’s platform—Business Operating System as a Service (BOSS) – is not another automation bot or AI assistant. It’s a full-stack orchestration engine built for the vertical complexity of healthcare, Instead of relying on humans to push paperwork or brittle bots that break when systems change, BOSS decomposes complex workflows into micro-tasks, then delegates them to a network of intelligent agents—LLMs, digital twins, and reinforcement learners, extending across an institution’s entire software stack. This allows BOSS to create a parallel digital workforce, operating on behalf of teams and alongside them. A 1,000-person institution can function like a 2,000-person one overnight, with digital agents making up half the workforce.
At a leading US cancer center, BOSS reduced prior authorization times from 30 minutes to under five. In just a few months, it processed over $1 million in medications, freed up 80 percent of staff time, and cut administrative costs by 66 percent.
Based in Silicon Valley, RISA is founded by IIT Kanpur alumni and repeat founders, Kshitij Jaggi (CEO) and Kumar Shivang (CTO) who’ve been friends for more than a decade now, who’ve previously built and scaled Urban Health. Their frustration with fragmented, slow, and error-prone healthcare workflows during that journey inspired the duo to take a systems-first approach, leading them to develop a foundational AI operating system that can simulate, understand, and orchestrate entire institutional workflows from end to end.
RISA’s founding team first explored these concepts through research, co-authoring ‘Digital Twin Ecosystem in Oncology Clinical Operations’—an early effort to envision smarter, AI-driven cancer care workflows. This foundational work laid the conceptual groundwork that later translated into tangible improvements in real-world oncology operations.
Looking ahead, RISA plans to extend across multiple nodes within the oncology ecosystem, positioning itself as the AI transformation partner for both operational and clinical workflows. This includes enabling coordination and intelligence across providers, life sciences organizations, and other stakeholders throughout the journey of a drug – extending the company’s long term vision to building a unified layer for AI-driven orchestration in oncology.
Share this:
Like this:
Related
This entry was posted on April 17, 2025 at 9:34 am and is filed under Commentary with tags RISA Labs. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.